Shannon Dahl

Shannon Dahl is a renowned leader in the biotechnology industry, known for her unique ability to drive innovation from early-stage research into the clinic and through to commercialization and reimbursement.  Throughout her career, Shannon has guided high-growth biotech therapeutics companies through critical phases of development. As the Founder and current CEO of Carve Bio, Shannon has provided C-suite leadership to a portfolio of therapeutics companies, inspiring teams to drive projects from early-stage research to successful INDs, into clinical trials, into partnerships and pipelines, and with clear paths to commercialization and reimbursement.

Previously, she co-founded Humacyte in 2004 and spent the next 14 years advancing a first-in-class allogeneic bioengineered blood vessel platform from R&D to global Phase 3 trials, building a strong pipeline, securing FDA’s first ever RMAT designation and negotiating a path to value-based reimbursement with CMS. She also serves on Strategic and Scientific Advisory Boards. With a Ph.D. in Biomedical Engineering from Duke University and a B.S. in Materials Sciences and Engineering from MIT, Shannon has built a formidable career marked by groundbreaking achievements and strategic leadership, consistently driving scientific initiatives from discovery to market readiness.

‍